¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ±è¼öÁöÀÔ´Ï´Ù.
Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº 2021³â nature communication ¿¡ ÃâÆǵÈ
"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice" ÀÔ´Ï´Ù.
ÀÌ ³í¹®¿¡¼´Â Novavax »ç¿¡¼ °³¹ßÇÑ SARS-CoV-2 subunit vaccine (NVX-CoV2373) ¿¡ ´ëÇÑ ¿¬±¸¸¦ ÁøÇàÇß½À´Ï´Ù. spike protein À» ±â¹ÝÀ¸·Î ¸¸µç ÀÌ ¹é½Å°ú saponin-based Matrix-M adjuvant ¸¦ ¸¶¿ì½º¿¡ immunization ÇÏ¿© ¸é¿ª¹ÝÀÀ°ú protection À» È®ÀÎÇßÀ¸¸ç ¿ø¼þÀÌ ¸ðµ¨¿¡¼µµ ÀÌ ¹é½ÅÀÇ È¿°ú¸¦ È®ÀÎÇÑ ³í¹®ÀÔ´Ï´Ù.
SARS-CoV-2 subunit vaccine ½ÇÇè °ü·Ã °øºÎ¸¦ À§ÇØ ¼±Á¤Çß½À´Ï´Ù.
Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
¼öÁö µå¸²
³í¹®»çÀÌÆ®: SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice | Nature Communications